A Phase 3 clinical trial involving eptinezumab was registered on October 23, 2026. The trial is titled "Early Infusion of Eptinezumab for Treatment of Acute Post-Traumatic Headaches," known as ELITE-ACT, with registry identifier NCT07191145.
According to the registry listing, the study is currently in Phase 3 and has a status of not yet recruiting. The trial is designed to examine early infusion of eptinezumab in the context of acute post-traumatic headaches, as indicated by its title.
No recruitment has started as of the listed date, and no outcomes, enrollment numbers, or efficacy data have been reported at this stage. This brief reflects only the registration details available on ClinicalTrials.gov at the time of publication. Further updates on recruitment status, participant enrollment, and eventual results would be expected as the trial progresses through subsequent phases of registration and reporting.
Readers interested in the broader context of calcitonin and related compounds, including eptinezumab, can consult the compound overview for additional background information.